Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-Month Comparison of New Insulin Glargine Formulation vs Lantus plus Mealtime Insulin in Type 2 Diabetes Mellitus
2010-023769-23Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline to month 6. Started Aug 2011; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-023769-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023769-23.